Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers

BACKGROUND: While immune checkpoint inhibitors (ICI) were approved for head and neck squamous cell carcinomas (HNSCCs), the response rate remains relatively low. Mechanisms underlying ICI unresponsiveness versus sensitivity are not fully understood. METHOD: To better delineate differential responses...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Samantha M. Y., Popolizio, Vince, Woolaver, Rachel A., Ge, Huaibin, Krinsky, Alexandra L., John, Jessy, Danis, Etienne, Ke, Yao, Kramer, Yonatan, Bian, Li, Nicklawsky, Andrew G., Gao, Dexiang, Liu, Silvia, Chen, Zhangguo, Wang, Xiao-jing, Wang, Jing H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976353/
https://www.ncbi.nlm.nih.gov/pubmed/35366939
http://dx.doi.org/10.1186/s13046-022-02337-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976353/
https://www.ncbi.nlm.nih.gov/pubmed/35366939
http://dx.doi.org/10.1186/s13046-022-02337-x

Ejemplares similares